Literature DB >> 10563341

Inhibitors of glucosylceramide synthase.

J A Shayman1, L Lee, A Abe, L Shu.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10563341     DOI: 10.1016/s0076-6879(00)11097-3

Source DB:  PubMed          Journal:  Methods Enzymol        ISSN: 0076-6879            Impact factor:   1.600


× No keyword cloud information.
  17 in total

Review 1.  Group XV phospholipase A₂, a lysosomal phospholipase A₂.

Authors:  James A Shayman; Robert Kelly; Jessica Kollmeyer; Yongqun He; Akira Abe
Journal:  Prog Lipid Res       Date:  2010-11-11       Impact factor: 16.195

Review 2.  Ceramide glycosylation catalyzed by glucosylceramide synthase and cancer drug resistance.

Authors:  Yong-Yu Liu; Ronald A Hill; Yu-Teh Li
Journal:  Adv Cancer Res       Date:  2013       Impact factor: 6.242

3.  Property-based design of a glucosylceramide synthase inhibitor that reduces glucosylceramide in the brain.

Authors:  Scott D Larsen; Michael W Wilson; Akira Abe; Liming Shu; Christopher H George; Paul Kirchhoff; H D Hollis Showalter; Jianming Xiang; Richard F Keep; James A Shayman
Journal:  J Lipid Res       Date:  2011-11-04       Impact factor: 5.922

4.  Reduction of globotriaosylceramide in Fabry disease mice by substrate deprivation.

Authors:  A Abe; S Gregory; L Lee; P D Killen; R O Brady; A Kulkarni; J A Shayman
Journal:  J Clin Invest       Date:  2000-06       Impact factor: 14.808

Review 5.  Lysosomal phospholipase A2.

Authors:  James A Shayman; John J G Tesmer
Journal:  Biochim Biophys Acta Mol Cell Biol Lipids       Date:  2018-08-02       Impact factor: 4.698

Review 6.  A turn in the road: How studies on the pharmacology of glucosylceramide synthase inhibitors led to the identification of a lysosomal phospholipase A2 with ceramide transacylase activity.

Authors:  James A Shayman; Akira Abe; Miki Hiraoka
Journal:  Glycoconj J       Date:  2004       Impact factor: 2.916

7.  VEGF recruits lactosylceramide to induce endothelial cell adhesion molecule expression and angiogenesis in vitro and in vivo.

Authors:  Antonina Kolmakova; Mohanraj Rajesh; David Zang; Roberto Pili; Subroto Chatterjee
Journal:  Glycoconj J       Date:  2009-02-14       Impact factor: 2.916

8.  Attenuation of acetic acid-induced gastric ulcer formation in rats by glucosylceramide synthase inhibitors.

Authors:  Manabu Nakashita; Hidekazu Suzuki; Soichiro Miura; Takao Taki; Keita Uehara; Tohru Mizushima; Hiroshi Nagata; Toshifumi Hibi
Journal:  Dig Dis Sci       Date:  2012-08-24       Impact factor: 3.199

Review 9.  Killing tumours by ceramide-induced apoptosis: a critique of available drugs.

Authors:  Norman S Radin
Journal:  Biochem J       Date:  2003-04-15       Impact factor: 3.857

10.  ELIGLUSTAT TARTRATE: Glucosylceramide Synthase Inhibitor Treatment of Type 1 Gaucher Disease.

Authors:  J A Shayman
Journal:  Drugs Future       Date:  2010-08-01       Impact factor: 0.148

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.